Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T90038
|
|||||
Target Name |
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway)
|
|||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Hyperlipidemia [ICD-11: 5C80] |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Drugs in Phase 3 Trial | [+] 1 | + | ||||
1 | Atorvastatin | Drug Info | Approved | Hyperlipidemia | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Atorvastatin | Drug Info | [1] |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042. | |||||
REF 2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.